Home › Diffuse Large B-Cell Lymphoma › Oklahoma › Oklahoma City
Diffuse Large B-Cell Lymphoma clinical trials in Oklahoma City, OK
5 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
RecruitingPhase 1/2
- University of Oklahoma, Oklahoma City
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Oklahoma, Oklahoma City
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Portland, OR15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer26 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer15 studies
- Cancer (all types)15 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Pancreatic Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.